Clinical Trials Sponsored by Cordis, Johnson&Johnson company

Total 73 results

University Heart Center Freiburg - Bad Krozingen
Cordis, Johnson&Johnson company

Unknown

Treatment of Bifurcated Coronary Lesions With Cypher™-Stent

Coronary Artery Disease

Germany
Johnson & Johnson K.K. Medical Company

Completed

Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)

Acute Ischemic Stroke

Japan
Johnson & Johnson K.K. Medical Company

Completed

Follow-up Study After Bankart Repair Using MG-1

Shoulder Dislocation

Japan
Johnson & Johnson K.K. Medical Company

Completed

A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Peripheral Vascular Diseases

Japan
Johnson & Johnson K.K. Medical Company

Completed

Open-Label Study for Shoulder Dislocation Using MG-1 (MG-1)

Shoulder Dislocation

Japan
AstraZeneca
Johnson & Johnson K.K. Medical Company

Completed

Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests

Gastrointestinal Endoscopy | Gastrointestinal Polypectomy

Japan
DePuy Orthopaedics
Johnson & Johnson K.K. Medical Company

Completed

DSJ-2016-07 ATTUNE® Cementless CR RP Japan

Osteoarthritis

Japan
Synthes GmbH
Johnson & Johnson K.K. Medical Company

Completed

Treatment of Medial Compartmental Osteoarthritis Grade 1-4 With TomoFix™ Small or Conservatively

Osteoarthritis, Knee | Osteonecrosis

Japan
Johnson & Johnson Vision Care, Inc.
Visioncare Research Ltd.; Johnson & Johnson K.K. Medical Company

Completed

Two Week Cross-Over Study Comparing Two Daily Disposable Contact Lenses

Myopia

Singapore
Johnson & Johnson Consumer Products Company Division...

Completed

Study of a Cold Sore Patch for the Treatment of Herpes Labialis

Herpes Labialis

United Kingdom
Johnson & Johnson Consumer Products Company Division...

Completed

Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100 (RIPT)

Allergic Sensitization

United States
Johnson & Johnson Consumer Products Company Division...

Completed

Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch

Microbiota

United States
Johnson & Johnson Consumer Products Company Division...

Completed

A Test of Different Kinds of Bandages on Healing of Wounds

Wound Healing

United States
Johnson & Johnson Consumer Products Company Division...

Completed

Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

Atopic Dermatitis

United States
Danderyd Hospital
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson...

Active, not recruiting

Periprosthetic Bone Remodeling Around Uncemented Components in Total Hip Arthroplasty (PeriBRUSBRAC)

Osteoarthritis

Sweden
Società Italiana di Cardiologia Invasiva
Cordis Italy a division of Johnson & Johnson Medical SpA

Unknown

GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions

Coronary Artery Disease

Italy
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Completed

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

Metastatic Malignant Neoplasm in the Liver | Adult Hepatocellular Carcinoma

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Recruiting

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Terminated

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage IV HPV-Mediated (p16-Positive)... and other conditions

United States
Jonsson Comprehensive Cancer Center
Kite, A Gilead Company

Completed

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Completed

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

Solid Tumor | Adult

United States
Johns Hopkins University
Eli Lilly and Company

Withdrawn

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

Priapism | Sickle Cell Anemia

United States
Johns Hopkins University
Eli Lilly and Company

Completed

Treatment of Executive Dysfunction in Parkinson's Disease

Parkinson's Disease

United States
Johns Hopkins University
Genzyme, a Sanofi Company

Withdrawn

Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)

Chronic Inflammatory Demyelinating Neuropathy

United States
Jonsson Comprehensive Cancer Center
Varian, a Siemens Healthineers Company

Active, not recruiting

Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Head and Neck Carcinoma

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8

United States
Johns Hopkins University
Doris Duke Charitable Foundation

Recruiting

Registry for Systemic Eczema Treatments (RESET)

Atopic Dermatitis

United States
Johns Hopkins University
Doris Duke Charitable Foundation

Recruiting

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Atopic Dermatitis

United States
University of Notre Dame
Infectious Diseases Research Collaboration, Uganda; SC Johnson, A Family Company and other collaborators

Not yet recruiting

Spatial Repellents for Malaria Control (AEGIS Uganda)

Malaria

Uganda
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Eli Lilly and Company

Completed

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

Head and Neck Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Withdrawn

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Stage IIB Melanoma | Stage IIC Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
Johns Hopkins Bloomberg School of Public Health
Quaker Oats Company

Completed

Effectiveness of Quaker Complete Nutrition Supplements for Malnourished Adults

Malnutrition

United States
Johns Hopkins University
National Eye Institute (NEI); Project ORBIS

Completed

Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia (STAR)

Trichiasis

United States
Jonsson Comprehensive Cancer Center
U.S. Army Medical Research and Development Command

Completed

Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women

Breast Cancer

United States
University of Notre Dame
Malaria Research and Training Center, Bamako, Mali; SC Johnson, A Family Company and other collaborators

Completed

Spatial Repellents for Vector Control (AEGIS Mali)

Malaria

Mali
Eastman Dental Insitute and Hospital
University College London Hospitals; Johnson & Johnson; British Heart Foundation and other collaborators

Completed

Effect of Intensive Periodontal Therapy on Vascular Function

Periodontitis

United Kingdom
University of Notre Dame
Centers for Disease Control and Prevention; Kenya Medical Research Institute; SC Johnson, A Family Company and other collaborators

Completed

Spatial Repellents for the Prevention of Malaria in Kenya (AEGIS Kenya)

Malaria

Kenya
Sidney Kimmel Comprehensive Cancer Center at Johns...
Eli Lilly and Company

Active, not recruiting

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genzyme, a Sanofi Company

Terminated

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (POE07-01)

Acute Myeloid Leukemia | Myeloproliferative Disorders | Myelofibrosis | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Promyelocytic Leukemia | Chronic Myelogenous Leukemia

United States, Canada
Johns Hopkins University
U.S. Army Medical Research and Development Command

Completed

Safety Study of Acellular Adipose Tissue for Soft Tissue Reconstruction

Healthy Volunteers

United States
Kirby Mayer
Nathan Johnson, PT, PhD; Ashley Montgomery-Yates, MD; Amy Pastva, PT, PhD; Peter...

Withdrawn

Redefining Survivorship: POWER to Maximize Physical Function for Survivors of Critical Illness (POWER)

Critical Illness | Muscle Atrophy or Weakness

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects

Type 2 Diabetes

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Unknown

Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM

Type 2 Diabetes
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes

Type 2 Diabetes

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
The University of Texas Health Science Center,...
U.S. Army Medical Research and Development Command; Ralph H. Johnson VA Medical...

Not yet recruiting

Transdiagnostic Behavior Therapy vs TAU for Adjustment Disorder Following Traumatic Event Exposure

Mental Disorder | Adjustment Disorders

United States
University of Notre Dame
University of Washington; SC Johnson, A Family Company; fhiClinical; Ministry of... and other collaborators

Recruiting

Spatial Repellents for Aedes-borne Virus Control in Sri Lanka (AEGIS ABV)

Arbovirus Infections

Sri Lanka
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Eli Lilly and Company

Completed

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Glioblastoma Multiforme

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Eli Lilly and Company; Merck Sharp & Dohme LLC

Completed

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States

Clinical Trials Sponsored by Cordis, Johnson&Johnson company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations